PL3455258T3 - Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1 - Google Patents

Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1

Info

Publication number
PL3455258T3
PL3455258T3 PL17726759T PL17726759T PL3455258T3 PL 3455258 T3 PL3455258 T3 PL 3455258T3 PL 17726759 T PL17726759 T PL 17726759T PL 17726759 T PL17726759 T PL 17726759T PL 3455258 T3 PL3455258 T3 PL 3455258T3
Authority
PL
Poland
Prior art keywords
administrating
inhibitor
treatment
methods
skin cancer
Prior art date
Application number
PL17726759T
Other languages
English (en)
Polish (pl)
Inventor
Israel Lowy
Matthew G. Fury
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3455258T3 publication Critical patent/PL3455258T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0604—Lungs and/or airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0605—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0606—Mouth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0607—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0608—Rectum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0609—Stomach and/or esophagus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0611—Vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17726759T 2016-05-13 2017-05-12 Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1 PL3455258T3 (pl)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662335743P 2016-05-13 2016-05-13
US201662340142P 2016-05-23 2016-05-23
US201662348546P 2016-06-10 2016-06-10
US201662350305P 2016-06-15 2016-06-15
US201662364920P 2016-07-21 2016-07-21
US201662374020P 2016-08-12 2016-08-12
US201762451274P 2017-01-27 2017-01-27
PCT/US2017/032408 WO2017197263A1 (en) 2016-05-13 2017-05-12 Methods of treating skin cancer by administering a pd-1 inhibitor
EP17726759.8A EP3455258B1 (en) 2016-05-13 2017-05-12 Methods of treating skin cancer by administering a pd-1 inhibitor

Publications (1)

Publication Number Publication Date
PL3455258T3 true PL3455258T3 (pl) 2022-02-28

Family

ID=58800911

Family Applications (3)

Application Number Title Priority Date Filing Date
PL17726759T PL3455258T3 (pl) 2016-05-13 2017-05-12 Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1
PL17727767.0T PL3455259T3 (pl) 2016-05-13 2017-05-12 Skojarzenie przeciwciał anty-pd-1 i radioterapii w celu leczenia nowotworu
PL21191931.1T PL3932951T3 (pl) 2016-05-13 2017-05-12 Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL17727767.0T PL3455259T3 (pl) 2016-05-13 2017-05-12 Skojarzenie przeciwciał anty-pd-1 i radioterapii w celu leczenia nowotworu
PL21191931.1T PL3932951T3 (pl) 2016-05-13 2017-05-12 Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1

Country Status (32)

Country Link
US (4) US10457725B2 (enExample)
EP (4) EP3932951B1 (enExample)
JP (4) JP7054680B2 (enExample)
KR (5) KR102595561B1 (enExample)
CN (4) CN116098997A (enExample)
AU (3) AU2017264959B2 (enExample)
BR (1) BR112018073291A2 (enExample)
CA (2) CA3023985A1 (enExample)
CL (1) CL2018003207A1 (enExample)
CY (1) CY1124901T1 (enExample)
DK (3) DK3455258T3 (enExample)
ES (3) ES2938321T3 (enExample)
FI (2) FI3455259T3 (enExample)
HR (3) HRP20230236T1 (enExample)
HU (3) HUE061417T2 (enExample)
IL (4) IL262562B2 (enExample)
LT (2) LT3932951T (enExample)
MD (3) MD3455258T2 (enExample)
MX (4) MX389733B (enExample)
MY (2) MY194085A (enExample)
NZ (1) NZ788452A (enExample)
PH (1) PH12018502263A1 (enExample)
PL (3) PL3455258T3 (enExample)
PT (3) PT3455258T (enExample)
RS (3) RS64218B1 (enExample)
SG (2) SG10202011110PA (enExample)
SI (3) SI3455258T1 (enExample)
SM (2) SMT202300070T1 (enExample)
TW (3) TWI755395B (enExample)
UA (1) UA124151C2 (enExample)
WO (2) WO2017197259A1 (enExample)
ZA (2) ZA201807050B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
WO2019143607A1 (en) * 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
US12358984B2 (en) 2018-02-13 2025-07-15 Merck Sharp & Dohme Llc Methods for treating cancer with anti-PD-1 antibodies
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN112074541A (zh) * 2018-05-03 2020-12-11 上海岸迈生物科技有限公司 Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
TWI890661B (zh) * 2018-06-21 2025-07-21 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
CA3107983A1 (en) 2018-07-23 2020-01-30 Guardant Health, Inc. Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage
KR20210052511A (ko) 2018-08-31 2021-05-10 가던트 헬쓰, 인크. 무세포 dna에서의 미세부수체 불안정성 검출
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3866804A4 (en) * 2018-10-19 2022-08-03 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020102375A1 (en) * 2018-11-14 2020-05-22 Regeneron Pharmaceuticals, Inc. Intralesional administration of pd-1 inhibitors for treating skin cancer
EP3880231A1 (en) * 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
MA54401A (fr) * 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Polythérapie associant des radioimmunoconjugués et des inhibiteurs de réparation des dommages à l'adn
EP3890802A4 (en) * 2018-12-08 2023-03-22 Board of Regents, The University of Texas System IDENTIFICATION AND TARGETING OF TUMOR-FOMOTING CARCINOMA ASSOCIATED WITH FIBROBLAST FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES
US12179037B2 (en) 2018-12-11 2024-12-31 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
AU2020211584A1 (en) * 2019-01-21 2021-08-26 Sanofi Therapeutic RNA for advanced stage solid tumor cancers
CN113365659B (zh) * 2019-01-31 2023-08-18 正大天晴药业集团股份有限公司 抗pd-l1抗体治疗头颈癌的用途
AU2020228296B2 (en) * 2019-02-28 2025-10-02 Regeneron Pharmaceuticals, Inc. Administration of PD-1 inhibitors for treating skin cancer
WO2020222231A1 (en) * 2019-04-28 2020-11-05 Institut Pasteur De Montevideo. Ionic channel modulation as a method for treating tumors through inflammasome activation
PH12021552675A1 (en) * 2019-05-13 2022-07-04 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
US20210169979A1 (en) * 2019-12-05 2021-06-10 The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges System and method for sonosensitized cancer immunotherapy with nanoparticles
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN115279456A (zh) 2020-01-28 2022-11-01 反射医疗公司 放射性核素与外部束放疗的联合优化
CN113318226A (zh) * 2020-02-28 2021-08-31 正大天晴药业集团股份有限公司 抗pd-l1抗体联合放射性射线治疗肺癌的方法
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
MA71214A (fr) * 2020-08-26 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
KR20230061499A (ko) * 2020-09-03 2023-05-08 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제 투여에 의한 암 통증 치료 방법
MX2023009279A (es) * 2021-02-11 2023-10-02 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
CN115125211A (zh) * 2021-03-24 2022-09-30 核工业总医院 免疫治疗疗效评价用结肠癌腹膜转移小鼠模型
CN113368226B (zh) * 2021-06-30 2021-11-30 上海力沃生物科技有限公司 含有dc瘤苗的药物组合物及其在治疗癌症中的应用
JP2024530190A (ja) * 2021-08-06 2024-08-16 アールズィーノミクス・インコーポレイテッド 放射線治療と併用される遺伝子治療剤として癌特異的なトランススプライシングリボザイム
US20230250176A1 (en) * 2022-02-09 2023-08-10 Dragonfly Therapeutics, Inc. Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
CN120584138A (zh) * 2023-02-06 2025-09-02 豪夫迈·罗氏有限公司 组合疗法及其用途
TW202509063A (zh) * 2023-08-21 2025-03-01 瑞士商百濟神州瑞士有限責任公司 用抗lag3、抗pd-1和化學療法治療食管癌
WO2025117889A2 (en) * 2023-11-30 2025-06-05 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
WO2002000730A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
JP2004104681A (ja) 2002-09-12 2004-04-02 Renesas Technology Corp 入力バッファ回路
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP4663394B2 (ja) 2005-05-11 2011-04-06 ダイセルポリマー株式会社 難めっき性被覆剤及びめっきの前処理方法
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
EP1997887B1 (en) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009024531A1 (en) 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
KR20120027055A (ko) 2009-06-26 2012-03-20 리제네론 파라마큐티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
IN2012DN01920A (enExample) 2009-09-03 2015-07-24 Schering Corp
AU2010303149B2 (en) 2009-09-30 2016-08-04 Board Of Regents, The University Of Texas System Combination immunotherapy for the treatment of cancer
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
MX343747B (es) 2009-11-24 2016-11-22 Medimmune Ltd Agentes de union diana contra b7-h1.
PL3095871T3 (pl) 2010-02-08 2019-10-31 Regeneron Pharma Mysz zawierająca wspólny łańcuch lekki
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2012062218A1 (en) 2010-11-11 2012-05-18 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
GB201120527D0 (en) 2011-11-29 2012-01-11 Ucl Business Plc Method
JP2015506372A (ja) 2012-01-27 2015-03-02 グリックニック インコーポレイテッド ＩｇＧ２ヒンジドメインを含む融合タンパク質
HK1207655A1 (en) 2012-05-04 2016-02-05 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US20130303250A1 (en) 2012-05-11 2013-11-14 Ryan Moore Method of Playing a Card Game
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
CN116271053A (zh) * 2012-08-13 2023-06-23 洛克菲勒大学 治疗和诊断黑素瘤
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2904011B1 (en) 2012-10-02 2017-08-23 Bristol-Myers Squibb Company Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
RS56531B1 (sr) 2013-03-14 2018-02-28 Bristol Myers Squibb Co Kombinacija dr5 agoniste i anti-pd-1 antagoniste i načini primene
MY176706A (en) 2013-03-15 2020-08-19 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
MX384142B (es) 2013-07-16 2025-03-14 Genentech Inc Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EP3035964B1 (en) 2013-08-20 2020-09-23 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and dinaciclib
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP4285928A3 (en) 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
WO2015088930A1 (en) 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
EP3527587A1 (en) * 2013-12-17 2019-08-21 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
CN106029696B (zh) 2013-12-17 2020-07-28 基因泰克公司 抗cd3抗体及使用方法
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2949121A1 (en) 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
BR112016029650A2 (pt) 2014-06-19 2017-10-24 Regeneron Pharma roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
PT3212233T (pt) * 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
IL292449B2 (en) 2015-03-13 2024-02-01 Cytomx Therapeutics Inc Nucleic acids encoding anti-pdl1 antibodie and methods of producing same
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
NZ740351A (en) 2015-09-03 2022-10-28 Ono Pharmaceutical Co Immunity enhancing agent for cancer by allergin-1 antagonist
PT3394103T (pt) 2015-12-22 2023-09-04 Regeneron Pharma Combinação de anticorpos anti-pd-1 e anticorpos biespecíj'icos anti-cd20/anti-cd3 para tratar cancro
EP3420000A1 (en) 2016-02-25 2019-01-02 Cell Medica Switzerland AG Modified cells for immunotherapy
US10736976B2 (en) 2016-12-01 2020-08-11 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

Also Published As

Publication number Publication date
EP3932951A1 (en) 2022-01-05
JP6999577B2 (ja) 2022-01-18
HUE061417T2 (hu) 2023-06-28
AU2017264959A1 (en) 2018-11-29
CL2018003207A1 (es) 2019-06-21
UA124151C2 (uk) 2021-07-28
KR20210154266A (ko) 2021-12-20
HUE057781T2 (hu) 2022-06-28
IL302924A (en) 2023-07-01
TW202313113A (zh) 2023-04-01
FI3932951T3 (fi) 2023-03-17
RS62783B1 (sr) 2022-01-31
SI3455258T1 (sl) 2022-01-31
IL302924B2 (en) 2025-07-01
JP7313493B2 (ja) 2023-07-24
MD3932951T2 (ro) 2023-04-30
US20170327567A1 (en) 2017-11-16
WO2017197263A1 (en) 2017-11-16
TWI786044B (zh) 2022-12-11
PL3455259T3 (pl) 2023-07-10
SI3455259T1 (sl) 2023-06-30
MX2022001120A (es) 2022-02-16
KR102470294B1 (ko) 2022-11-28
ES2943640T3 (es) 2023-06-15
RS64014B1 (sr) 2023-03-31
CN116407627A (zh) 2023-07-11
MX2022001123A (es) 2022-02-16
IL302924B1 (en) 2025-03-01
TWI755395B (zh) 2022-02-21
RS64218B1 (sr) 2023-06-30
EP3455258A1 (en) 2019-03-20
US10457725B2 (en) 2019-10-29
ZA201807050B (en) 2019-07-31
KR102464774B1 (ko) 2022-11-09
LT3455258T (lt) 2021-12-10
IL318482A (en) 2025-03-01
MY194085A (en) 2022-11-11
PT3932951T (pt) 2023-02-22
TW202408578A (zh) 2024-03-01
SI3932951T1 (sl) 2023-04-28
FI3455259T3 (fi) 2023-05-10
ES2938321T3 (es) 2023-04-10
CN109153724A (zh) 2019-01-04
EP4180459A1 (en) 2023-05-17
EP3455259A1 (en) 2019-03-20
DK3455259T3 (da) 2023-05-15
JP7054680B2 (ja) 2022-04-14
TWI822521B (zh) 2023-11-11
WO2017197259A1 (en) 2017-11-16
DK3455259T5 (da) 2024-09-09
DK3932951T5 (da) 2024-08-05
US20200010538A1 (en) 2020-01-09
HRP20230517T1 (hr) 2023-08-04
PL3932951T3 (pl) 2023-04-11
DK3932951T3 (da) 2023-02-27
EP3455259B1 (en) 2023-03-01
SMT202200015T1 (it) 2022-03-21
HRP20220014T1 (hr) 2022-04-01
NZ788452A (en) 2025-11-28
CA3023984A1 (en) 2017-11-16
KR20220153681A (ko) 2022-11-18
EP3455258B1 (en) 2021-10-13
US20170327590A1 (en) 2017-11-16
KR102595561B1 (ko) 2023-10-30
JP2019519499A (ja) 2019-07-11
AU2017264959B2 (en) 2024-07-25
MX2018013847A (es) 2019-02-14
AU2017264955B2 (en) 2024-05-23
IL262561B (en) 2022-05-01
MY208872A (en) 2025-06-05
PT3455259T (pt) 2023-05-04
MX2018013848A (es) 2019-02-14
IL262562B1 (en) 2023-07-01
US11505600B2 (en) 2022-11-22
SMT202300070T1 (it) 2023-05-12
CN116098997A (zh) 2023-05-12
JP2022050618A (ja) 2022-03-30
KR20190007046A (ko) 2019-01-21
BR112018073291A2 (pt) 2019-03-19
PH12018502263A1 (en) 2019-09-23
CN109153724B (zh) 2023-02-21
KR102349056B1 (ko) 2022-01-11
AU2024220021A1 (en) 2024-10-17
IL262562A (en) 2018-12-31
HRP20230236T1 (hr) 2023-04-14
JP2023123848A (ja) 2023-09-05
US20230227542A1 (en) 2023-07-20
MD3455259T2 (ro) 2023-07-31
TW201806616A (zh) 2018-03-01
PT3455258T (pt) 2021-12-29
SG10202011110PA (en) 2020-12-30
MD3455258T2 (ro) 2022-02-28
IL262561A (en) 2018-12-31
TW201808330A (zh) 2018-03-16
MX389733B (es) 2025-03-20
NZ748192A (en) 2024-03-22
CY1124901T1 (el) 2023-01-05
HUE061874T2 (hu) 2023-08-28
EP3932951B1 (en) 2022-12-07
AU2017264955A1 (en) 2018-11-29
ZA201807051B (en) 2019-08-28
JP7624033B2 (ja) 2025-01-29
CN109153723A (zh) 2019-01-04
CA3023985A1 (en) 2017-11-16
ES2899954T3 (es) 2022-03-15
LT3932951T (lt) 2023-02-27
SG11201809554VA (en) 2018-11-29
KR20190007488A (ko) 2019-01-22
CN109153723B (zh) 2023-10-27
DK3455258T3 (da) 2021-12-20
KR20230152804A (ko) 2023-11-03
IL262562B2 (en) 2023-11-01
JP2019515008A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
PL3455258T3 (pl) Sposoby leczenia nowotworu skóry przez podawanie inhibitora pd-1
IL269026A (en) Methods of treating tumor
IL258955A (en) Compositions and methods for treatment of cancer
IL249065A0 (en) Combination therapies for the treatment of cancer
IL263224A (en) Methods and compositions for treating cancers
PL3283527T3 (pl) Leczenie skojarzone nowotworów
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3288581T3 (pl) Sposób leczenia nowotworu
IL255261A0 (en) Methods for treating cancer
PL3426271T3 (pl) Sposoby leczenia guzów litych terapią skojarzoną
PL3265053T3 (pl) Sposoby leczenia skóry
HUE049591T2 (hu) Makrociklusos MCL-1 inhibitorok rák kezelésére
HUE059694T2 (hu) Készítmény rák kezelésére
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
IL258521B1 (en) Combination therapy for the treatment of cancer
IL263802A (en) Cancer treatment combinations
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
IL250344B (en) Dioxolane analogues of uridine for the treatment of cancer
PT3622953T (pt) Tratamento combinado do cancro
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
IL252096A0 (en) Microneedle arrays for cancer therapy applications
IL268728A (en) Formulations of cannabinoids for the treatment of acne
DK3576740T3 (da) Cancerbehandling
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére